Hikma profit jumps on strong injectible drug sales

March 11 (Reuters) - Hikma Pharmaceuticals Plc (LSE: HIK.L - news) reported a 21 percent rise in full-year pretax profit, helped by strong demand for its high-margin injectible drugs, particularly in the United States.

The Jordanian company, which makes and markets branded and non-branded generics and injectible drugs, also said it expected 2015 revenue growth of about 6 percent in constant currency terms.

Pretax profit rose to $362 million in the year ended Dec. 31, from $298 million a year earlier.

Revenue rose 9 percent to $1.49 billion. (Reporting by Roshni Menon in Bengaluru; Editing by Gopakumar Warrier)